浙江燎原药业有限公司
Zhejiang Liaoyuan Pharmaceutical Co. Ltd. Duqiao Town Cn
Country: CN CDE+DMF+CEP MEDIUM
🇨🇳 CDE
12
12 products shown
🇺🇸 DMF
5
5 products shown
🇪🇺 CEP
7
7 products shown
Total
24
registrations
🇨🇳 CDE 注册 (12)
| Product | CAS | Status | Reg Number |
|---|---|---|---|
| Apixaban 阿哌沙班 | 503612-47-3 | Class A | Y20200000407 |
| Butylphthalide 丁苯酞 | 6066-49-5 | Class A | Y20230000118 |
| Clopidogrel 氯吡格雷 | 113665-84-2 | Class A | Y20200000870 |
| Duloxetine 盐酸度洛西汀 | 116539-59-4 | Class A | Y20170000997 |
| Ferric Carboxymaltose 羧基麦芽糖铁 | 98063-73-1 | Class I | Y20240001553 |
| Ivabradine 盐酸伊伐布雷定 | 155974-00-8 | Class A | Y20210001135 |
| Mirtazapine 米氮平 | 85650-52-8 | Class A | Y20200000669 |
| Moxifloxacin 盐酸莫西沙星 | 151096-09-2 | Class A | Y20210000103 |
| Rebamipide 瑞巴派特 | 90098-04-7 | Class A | Y20220000977 |
| Relmapirazin 瑞玛比嗪 | 1313706-17-0 | Class A | Y20230000859 |
| Rivaroxaban 利伐沙班 | 366789-02-8 | Class A | Y20200000798 |
| Safinamide 甲磺酸沙非胺 | 133865-89-1 | Class I | Y20240000138 |
🇺🇸 DMF 注册 (5)
| Product | CAS | DMF Number | Date |
|---|---|---|---|
| 1-(3-hydroxymethylpyridyl-2)-2-phenyl-4-methylpiperazine | - | 34266 | 2019-11-06 |
| Apixaban 阿哌沙班 | 503612-47-3 | 34071 | 2019-09-30 |
| Clopidogrel Hydrogen Sulfate | 120202-66-6 | 41953 | 2025-05-26 |
| Ivabradine Hydrochloride 盐酸伊伐布雷定 | 148849-67-6 | 32616 | 2019-10-23 |
| Mirtazapine 米氮平 | 85650-52-8 | 42160 | 2025-06-25 |
🇪🇺 CEP 注册 (7)
| Product | CAS | CEP Number | Date |
|---|---|---|---|
| Clopidogrel Hydrogen Sulfate | 120202-66-6 | R1-CEP 2015-156 - Rev 00 | 2021-07-15 |
| Clopidogrel Hydrogen Sulfate, Process B | 120202-66-6 | R0-CEP 2020-159 - Rev 00 | 2026-06-03 |
| Clopidogrel Hydrogen Sulfate, Process C | 120202-66-6 | R0-CEP 2021-414 - Rev 00 | 2026-09-16 |
| Duloxetine Hydrochloride 盐酸度洛西汀 | 136434-34-9 | R1-CEP 2014-239 - Rev 00 | 2020-08-28 |
| Mirtazapine 米氮平 | 85650-52-8 | R1-CEP 2009-180 - Rev 02 | 2026-09-17 |
| Mirtazapine, Anhydrous 米氮平 | 85650-52-8 | CEP 2020-158 - Rev 02 | 2025-05-23 |
| Ticlopidine Hydrochloride 盐酸噻氯匹定 | 53885-35-1 | R1-CEP 2004-109 - Rev 03 | 2021-05-03 |
Source: ema_cep;FDA_DMF | Updated: 2026-10-27 06:00:13